- Home
- BDJ vs TVTX Comparison
BDJ vs TVTX Comparison
Compare BDJ & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDJ
- TVTX
- Stock Information
- Founded
- BDJ 2005
- TVTX 2008
- Country
- BDJ United States
- TVTX United States
- Employees
- BDJ N/A
- TVTX N/A
- Industry
- BDJ Finance Companies
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- BDJ Finance
- TVTX Health Care
- Exchange
- BDJ Nasdaq
- TVTX Nasdaq
- Market Cap
- BDJ 1.5B
- TVTX 1.4B
- IPO Year
- BDJ N/A
- TVTX N/A
- Fundamental
- Price
- BDJ $8.90
- TVTX $16.91
- Analyst Decision
- BDJ
- TVTX Strong Buy
- Analyst Count
- BDJ 0
- TVTX 16
- Target Price
- BDJ N/A
- TVTX $33.33
- AVG Volume (30 Days)
- BDJ 561.6K
- TVTX 1.4M
- Earning Date
- BDJ 01-01-0001
- TVTX 07-31-2025
- Dividend Yield
- BDJ 8.85%
- TVTX N/A
- EPS Growth
- BDJ N/A
- TVTX N/A
- EPS
- BDJ N/A
- TVTX N/A
- Revenue
- BDJ N/A
- TVTX $273,533,000.00
- Revenue This Year
- BDJ N/A
- TVTX $73.84
- Revenue Next Year
- BDJ N/A
- TVTX $46.72
- P/E Ratio
- BDJ N/A
- TVTX N/A
- Revenue Growth
- BDJ N/A
- TVTX 75.65
- 52 Week Low
- BDJ $6.91
- TVTX $7.93
- 52 Week High
- BDJ $8.66
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- BDJ 63.62
- TVTX 62.88
- Support Level
- BDJ $8.88
- TVTX $14.44
- Resistance Level
- BDJ $8.97
- TVTX $16.64
- Average True Range (ATR)
- BDJ 0.08
- TVTX 0.63
- MACD
- BDJ 0.01
- TVTX 0.34
- Stochastic Oscillator
- BDJ 88.10
- TVTX 86.15
About BDJ Blackrock Enhanced Equity Dividend Trust
BlackRock Enhanced Equity Dividend Trust is a United States closed-end management investment company. Its investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.